How has been the historical performance of Biogen Pharma?

Answer:The historical performance of Biogen Pharma shows a fluctuating trend in its financial metrics over the years, with significant challenges in generating consistent revenue and profit.

Breakdown:
Biogen Pharma's net sales have been inconsistent, with figures of 2.47 Cr in March 2022, dropping to 0.00 Cr in March 2023, 2024, and 2025. Other operating income has also varied, peaking at 2.38 Cr in March 2024 before declining to 0.84 Cr in March 2025. Total operating income followed a similar pattern, reaching 2.16 Cr in March 2022 but falling to 0.84 Cr by March 2025. The company faced high total expenditure in March 2022 at 2.18 Cr, which decreased to 1.13 Cr in March 2025. Operating profit, excluding other income, was negative in March 2025 at -0.29 Cr, contrasting with a positive 1.93 Cr in March 2024. The profit before tax mirrored this trend, with a loss of -0.29 Cr in March 2025 compared to a profit of 1.93 Cr in March 2024. Consequently, the profit after tax also reflected a loss of -0.29 Cr in March 2025, following a profit of 1.93 Cr in the previous year. The company's total assets increased slightly from 54.83 Cr in March 2023 to 56.82 Cr in March 2024, while total liabilities remained stable, indicating a lack of significant financial leverage. Cash flow from operating activities remained steady at 1.00 Cr for the last three years, but cash flow from investing activities showed a negative trend, indicating ongoing investments or expenditures. Overall, Biogen Pharma's financial performance has been marked by volatility, with recent years showing a struggle to maintain profitability and revenue generation.